Baixuan Xu
Papers
1
Total Citations
19
H-Index
1
About
Baixuan Xu is a pioneering urologic oncologist whose research is reshaping the diagnostic pathway for prostate cancer. His work centers on the integration of advanced molecular imaging—specifically, PSMA-ligand PET/CT and multiparametric MRI—to improve risk stratification and guide surgical decision-making. Xu’s most notable contribution is his landmark 2024 prospective, single-arm trial, which demonstrated the feasibility of performing radical prostatectomy without prior biopsy in carefully selected patients. By using PSMA-PET and MRI to identify high-risk, localized disease, his study challenges the long-standing dogma that histologic confirmation is mandatory before definitive treatment. This work, already garnering 19 citations, has sparked critical discussion about reducing unnecessary biopsies and their associated morbidity. Xu’s research directly addresses the clinical need for more precise, less invasive diagnostic algorithms. His findings not only offer a potential paradigm shift in early prostate cancer management but also underscore the growing role of molecular imaging in personalizing surgical oncology. For students and researchers, Xu represents a bold, evidence-driven voice at the intersection of imaging innovation and surgical practice.
Research Focus
Key Achievements
Top Papers
- 1